GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover

SMFR 11.19.2024

Full Press ReleaseSEC FilingsOur SMFR Tweets

About Gravity Analytica

Recent News

  • 01.17.2025 - GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - GeneDx Announces Preliminary 2024 Financial Results

Recent Filings

  • 01.22.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.13.2025 - 3 Initial statement of beneficial ownership of securities
  • 01.13.2025 - 8-K Current report

New Biopharma Solution Aims to Accelerate the Delivery of Precision Medicine to More Patients

STAMFORD, Conn.--(BUSINESS WIRE)--Nov. 19, 2024--GeneDx(Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GeneDx Discover, a first-of-its-kind data visualization tool, which provides biopharmaceutical companies access to deidentified and aggregated genetic data - powered by GeneDx’s robust database - to improve all stages of drug development. The new offering is part of GeneDx’s ongoing investment to deliver personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery.

Today’s drug discovery and development process is not scalable to meet society’s growing needs. On average, developing a new therapy costs$2.6B, takes 12 years, and fails 90% of the time. This data represents today's long and expensive clinical development cycles that too often fail due to safety and/or efficacy issues.1,2These high costs, lengthy development periods, and overwhelming failure rates are unsustainable, especially as science and technology advance to address critical therapy gaps both in theU.S.and globally.

Genetic data is a powerful tool that can significantly enhance the therapeutic development process, including reducing costs, accelerating timelines, and increasing success rates1. With access to genetic diagnoses continuing to expand, the impact of genetics on therapeutic development is growing. With more than 700,000 clinical exomes and genomes, GeneDx’s industry leading dataset is one of the most sophisticated in the industry and can now be leveraged as a solution for biopharmaceutical companies to drive evidence-based decision making and accelerate the development of new treatments.

"With nearly 25 years of expertise in clinical genetic data,GeneDxholds a wealth of genetic evidence that plays a critical role in transforming patient care and unlocking new drug development opportunities," saidMelanie Duquette, Chief Growth Officer atGeneDx. "GeneDx Discover is a data-driven solution that empowers our biopharma partners to better understand the genetic underpinnings of diseases, their prevalence in diverse patient populations and accelerate the development of targeted therapies—helping bring effective treatments to more patients, faster."

GeneDx Discover is a self-service tool which leverages real-world data to enable a deeper understanding of the characteristics of target patient populations. The easy-to-use tool combines disease prevalence and phenotypic information, alongside variant-level details, unlocking a deeper understanding of the size and unique characteristics of the total addressable market for genetically-defined disease cohorts, and obtaining variant-level resolution to define the cohort. Through GeneDx Discover, partners have access to demographics, geographic disease distribution, variant information and the ability to filter searches by Human Phenotype Ontology (HPO) to refine cohorts based on specific phenotypic features.

"GeneDx'sdatabase is a powerful resource that can help drive the future of drug discovery, unlocking critical tools for target validation and understanding how these patient populations are growing,” saidYael Weiss, CEO of Mahzi Therapeutics. “By accessing genetic data, we can accelerate the development of precision therapies, offering new hope for patients with rare diseases. In the pursuit of innovative treatments, the integration of genetic information is not just a step forward—it's the key to unlocking transformative, life-changing solutions."

Through its various partnerships,GeneDxcollaborates with biopharmaceutical companies to increase patient access to genetic testing and speed up the development of treatments for rare diseases. Earlier this year,GeneDxlaunched aPatient Access Program,aimed at expanding access to exome testing for pediatric patients with unexplained epilepsy. GeneDx Discover is the latest offering fromGeneDxfor biopharmaceutical companies to leverage crucial genetic information that can impact patients' lives. To learn more visitwww.genedx.com/biopharma.

AboutGeneDx:GeneDx(Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care.GeneDxis at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation services, fueled by the world’s largest, rare disease data sets. For more information, please visitwww.genedx.comand connect with us onLinkedIn,Facebook, andInstagram.

References:

1Minikel, E.V., Painter, J.L., Dong, C.C.et al.Refining the impact of genetic evidence on clinical success.Nature629, 624–629 (2024)

2Paul, S., Mytelka, D., Dunwiddie, C.et al.How to improve R&D productivity: the pharmaceutical industry's grand challenge.Nat Rev Drug Discov9, 203–214 (2010)

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241119507394/en/

Press@genedx.comInvestors@genedx.com

Source:GeneDx

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com